OM1, Inc.

💡 Conducting large-scale studies can be overwhelming—inefficiencies, high costs, and complex data needs often hold up timelines. OM1 is here to change that. Automated real-world data collection tackles these challenges, enabling researchers to: ✅ Reduce costs and time with scalable, automated data collection ✅ Unlock insights from unstructured data like imaging and clinical notes with AI ✅ Ensure diverse, comprehensive datasets to meet regulatory standards and drive meaningful results Medical Affairs Professional Society (MAPS) #DataAutomation #MedicalAffairs #AI #RealWorldEvidence

⏰ T-3 days until #MAPS2025! Make sure to stop by our session on Monday to learn about driving differentiated messaging with real-world data and AI. And don't forget to visit us at booth #711! Medical Affairs Professional Society (MAPS) Joseph Zabinski, Ph.D., M.E.M. Kathryn Starzyk Mark Hogendobler Bradley Snipes #AI #MachineLearning #MedicalAffairs #MAPSAnnualMeeting

💡 Did you know that 80% to 100% of data collected in most clinical trials and studies is passive data? 💰 It is usually collected manually, which is expensive and burdensome on sites, especially in large studies. In the latest episode of Behind the Insights, Rich Gliklich breaks down how automation is the key to capturing passive data without manual effort. #DataAutomation #RealWorldData #ClinicalTrials

To drive meaningful impact in drug development, researchers need scalable, high-quality data that is fit-for-purpose. Explore faster decision-making, deeper insights, and more effective evidence generation with the OM1 Europe Team at DIA Europe! 📆 Schedule your meeting here: https://okt.to/vskz1y #DIAEurope #RandD #DrugDevelopment #Pharma

🔎 Traditional commercial strategies focus on known patient populations— but what about patients who aren’t on the radar? Join OM1 experts in an upcoming webinar with Fierce Pharma to learn how commercial teams can leverage AI-driven real-world insights and ensure their therapies reach the patients who need them most. 📍Sign up here 👉 https://okt.to/8Zml9w Joseph Zabinski, Ph.D., M.E.M. Kathryn Starzyk #CommercialPharma #FiercePharma #AI #MachineLearning

🕐As we count down to our Annual Americas Meeting in New Orleans, we are thrilled to dedicate each week to recognizing our incredible sponsors who are essential to the success of our 2025 event. 👏👏👏Your unwavering support fuels our mission at MAPS and strengthens the Medical Affairs community. Together, we're driving meaningful change for medical professionals and patients around the globe. Thank you for being a vital part of this journey! #MAPS2025 #MakingADifference #ThankYou #MedicalAffairs #MedicalAffairsIndustry #MedicalAffairsCommunity #MedicalAffairsProfessionalSociety DistillerSR Epikast Envision Pharma Group EVERSANA H1 Havas People US ICON plc ideaPoint - an Anaqua Company Indegene infograph-ed Inizio ThoughtLabs IPG Health IQVIA Klick Komodo Health Lockwood Lumanity Med Communications MedComms Experts Medscape Neolytica - A QPharma Company OM1, Inc. Onomi OPEN Health Oxford PharmaGenesis Parexel PharmaReview Digital Science Healthcare Consultancy Group - HCG Inspire Aissel Technologies

📢 Boston-based Pharma Professionals – You’re Invited! Join us for the first OM1 Symposium on Innovation in Evidence Generation, where a panel of industry experts will explore cutting-edge advancements shaping the future of real-world data and evidence generation. 🔎 Why You Should Attend: ✅ Private access to industry leaders from top-tier pharma companies ✅ Collaborative dialogue with industry leaders in RWD, AI, and more ✅ Exclusive insights that will define the next wave of industry advancements 📍To RSVP, email us at info@om1.com

⌛ Medical Affairs teams face growing pressure to deliver timely, evidence-based insights while navigating gaps in traditional research methods. Explore how tech-enabled real-world data analysis and AI-powered digital phenotyping can help Medical Affairs professionals accelerate time to insight, strengthen MSL and provider communications, and support strategic evidence plans at the Medical Affairs Professional Society (MAPS) Americas Meeting. Joseph Zabinski, Ph.D., M.E.M. Kathryn Starzyk #MAPSNOLA2025 #MedicalAffairs #AI #DigitalPhenotyping

🎙️🌟 NEW Behind the Insights: The Next Era of Evidence Generation with Rich Gliklich 🔎 What you'll learn in this episode: ✅ Promising innovations addressing high costs and timelines in clinical trials ✅ Advantages of leveraging automated data collection ✅ How to ensure ensure scalability and flexibility in nuanced data collection 📍Watch the full episode here: https://okt.to/vK3sLM 📩 Stay updated on future episodes: https://okt.to/IW8zqd

To drive meaningful impact in drug development, researchers need scalable, high-quality data that is fit-for-purpose. Explore faster decision-making, deeper insights, and more effective evidence generation with the OM1 Europe Team at DIA Europe! 📆 Schedule your meeting here: https://okt.to/vskz1y #DIAEurope #RandD #DrugDevelopment #Pharma